

Press Release

October 30, 2026

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Variances Between Consolidated Financial Forecasts and Actual Results for the Six Months Ended September 30, 2026 and Revisions to Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2027

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code 4506, Prime Market of TSE; hereinafter the "Company") announced today that there were variances between its consolidated financial forecasts for the six months ended September 30, 2026, which were announced on July 31, 2026, and the actual results for the period, which were released today.

The Company also announced that, in light of recent performance trends, it has revised its consolidated financial forecasts for the fiscal year ending March 31, 2027, which were announced on May 13, 2026.

1. Variances Between Its Consolidated Financial Forecasts and the Actual Results for the Six Months Ended September 30, 2026 (April 1, 2026 to September 30, 2026)

	Revenue	Core operating profit	Operating profit	Net profit attributable to owners of the parent	Basic earnings per share
	Millions of JPY	Millions of JPY	Millions of JPY	Millions of JPY	JPY
Previous forecasts (A)	251,000	30,000	30,000	26,000	58.80
Actual results (B)	266,490	42,123	42,276	38,238	86.48
Variance (B-A)	15,490	12,123	12,276	12,238	—
Variance (%)	6.2	40.4	40.9	47.1	—
[Reference] Corresponding period of the previous year (Six months ended September 30, 2025)	227,122	96,084	96,157	98,860	248.84

2. Revisions to Its Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

	Revenue	Core operating profit	Operating profit	Net profit attributable to owners of the parent	Basic earnings per share
	Millions of JPY	Millions of JPY	Millions of JPY	Millions of JPY	JPY
Previous forecasts (A)	540,000	91,000	90,000	77,000	172.89
Revised forecasts (B)	565,000	105,000	104,000	94,000	211.07
Variance (B-A)	25,000	14,000	14,000	17,000	—

Variance (%)	4.6	15.4	15.6	22.1	—
[Reference] Previous year (Year ended March 31, 2026)	453,294	105,908	107,338	106,865	268.99

Note: Core operating profit is its original performance indicator and is calculated by deducting certain items from operating profit. The deduction items mainly include impairment losses, business structure improvement expenses, and changes in fair value of contingent consideration.

3. Reasons for the Variances and the Revisions

(1) The six months ended September 30, 2026

Revenue increased by 15.5 billion JPY from the previous forecast to 266.5 billion JPY, primarily due to strong sales in the U.S., led by GEMTESA® (therapeutic agent for overactive bladder), as well as a weaker-than-expected yen.

Meanwhile, excluding foreign exchange effects, selling, general and administrative expenses and R&D expenses were slightly lower than expected. Consequently, compared with the previous forecasts, core operating profit increased by 12.1 billion JPY to 42.1 billion JPY, and operating profit by 12.3 billion JPY to 42.3 billion JPY.

Net profit attributable to owners of the parent increased by 12.2 billion JPY from the previous forecast to 38.2 billion JPY due to the increase in operating profit.

(2) The fiscal year ending March 31, 2027

In these revised forecasts, the Company has revised its assumed average exchange rate for the full fiscal year from 155.0 JPY/USD to 157.0 JPY/USD.

Revenue has been revised upward by 25.0 billion JPY from the previous forecast to 565.0 billion JPY, reflecting the expectation that sales in the U.S., led by GEMTESA®, will exceed the initial forecast, as well as an increase arising from the revised foreign exchange assumption.

Core operating profit has been revised upward by 14.0 billion JPY from the previous forecast to 105.0 billion JPY, reflecting an expected increase in gross profit driven by higher revenue, despite an anticipated increase in selling expenses associated with further commercial expansion.

Reflecting the increase in core operating profit, operating profit has been revised upward by 14.0 billion JPY from the previous forecast to 104.0 billion JPY, and net profit attributable to owners of the parent has been revised upward by 17.0 billion JPY to 94.0 billion JPY.

Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the date of this release, which involve both known and unknown risks and uncertainties. Actual results may differ materially from the forecasts and other forward-looking statements contained in this press release due to various factors.

Contact:

Corporate Communications,

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp